^
Association details:
| Biomarker: | MAP2K1 G128D + KRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
Excerpt:
GSK1120212 resistance was associated with acquired mutations in MEK1 (MEK1V211D mutation in BRAF-mutant RKO and MEK1G128D/L215P mutations in KRAS-mutant HCT116; Fig. 3C)….SCH772984 is equally potent in naïve or GSK1120212-resistant, BRAF-mutant RKO colorectal cancer cells (RKOMR) or KRAS-mutant HCT116 colorectal cancer cells (HCT116MR).
DOI:
10.1158/2159-8290.CD-13-0070
